HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | Avapritinib | Ayvakit | 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
NA | Ripretinib | Qinlock | 50mg | Chemotherapy | Tyrosine Kinase Inhibitor | KIT, PDGFRA | Yes | 2020 | In Use | |||
NA | Alpelisib | Piqray | 200mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2019 | In Use | |||
NA | Axitinib | Axitinib | 5 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
J8999 | Chemotherapy - non specific | Prescription drug, oral, chemotherapeutic NOS | NA | Chemotherapy | Yes | In Use | ||||||
Tovorafenib | Ojemda | 25mg, 100mg | Chemotherapy | Enzyme Inhibitor | BRAF, CRAF | Yes | 2024 | In Use | ||||
NA | Anagrelide | Agrylin | 0.5mg | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Yes | 1997 | In Use | |||
NA | Dacomitinib | Vizimpro | 15mg, 30mg, 45mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2018 | In Use | |||
NA | Apalutamide | Erleada | 60mg | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Yes | 2018 | In Use | |||
NA | Selpercatinib | Retevmo | 40mg, 80mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2020 | In Use | |||
NA | Afatinib | Gliotrif | 30 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2013 | In Use | |||
Asciminib | Scemblix | 20mg,40mg | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Yes | 2021 | In Use | ||||
NA | Trifluridine and Tipiracil | Lonsurf | 15/6.14 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | Yes | 2015 | In Use | |||
NA | Altretamine | Hexalen | 50 mg | Chemotherapy | Alkylating Agent | Triazines | Yes | 1990 | 2019 | In Use | ||
NA | Ketoconazole | Apo-Ketoconazole | 200 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Imidazole Derivative | Yes | 1981 | In Use | |||
NA | Dasatinib | Sprycel | 70 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
Lazertinib | Lazcluze | 80mg, 240mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2024 | In Use | ||||
NA | Ceritinib | Zykadia | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2014 | In Use | |||
NA | Vandetanib | Caprelsa | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Yes | 2011 | In Use | |||
Momelotinib | Ojjaara | Multiple | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2023 | In Use | ||||
NA | Avapritinib | Ayvakit | 300mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
Q9978 | Netupitant/palonostron | Akynzeo | 300mg/0.5 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Yes | 2014 | Jul 1, 2015 | Dec 31, 2015 | No Longer Used | |
NA | Thalidomide | Thalomid | 200 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
NA | Alpelisib | Piqray | 150mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2019 | In Use | |||
NA | Brigatinib | Alunbrig | 30 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2017 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.